Safety outcomes of remdesivir for treatment of COVID-19 hospitalised patients in Indonesia
DOI:
https://doi.org/10.46542/pe.2024.243.348352Keywords:
COVID-19, Infectious disease, Kidney function, Liver function, RemdesivirAbstract
Background: Remdesivir has been granted emergency use authorisation for hospitalised COVID-19 patients. However, the available evidence in Indonesia is limited to related liver and kidney injuries.
Objective: This study aims to assess the safety of remdesivir based on liver and kidney function and its association with comorbidity and disease severity.
Method: This retrospective study evaluated remdesivir's efficacy in hospitalised COVID-19 patients of varying severity by collecting baseline and follow-up data on aspartate aminotransferase (AST), alanine aminotransferase (ALT), Glomerular filtration rate (GFR) and Blood urea nitrogen (BUN).
Result: In this study, 189 patients with elevated transaminase enzyme levels were given hepatoprotection therapy. Patients who did not receive the treatment experienced a significant rise in ALT levels (p < 0.001), while BUN levels increased significantly (p = 0.001) but within the normal range. There was no worsening of GFR value (p < 0.001), and no significant association was found between AST and ALT levels with comorbidity and disease severity (p < 0.001; OR 50.202).
Conclusion: Remdesivir demonstrated good tolerability despite increased ALT and BUN without correlating to comorbidity or disease severity in COVID-19.
References
Adamsick, M. L., Gandhi, R. G., Bidell, M. R., Elshaboury, R. H., Bhattacharyya, R. P., Kim, A. Y., Nigwekar, S., Rhee, E. P., & Sise, M. E. (2020). Remdesivir in patients with acute or chronic kidney disease and COVID-19. Journal of the American Society of Nephrology, 31(7), 1384–1386. https://doi.org/10.1681/ASN.2020050589
Ansems, K., Grundeis, F., Dahms, K., Mikolajewska, A., Thieme, V., Piechotta, V., Metzendorf, M. I., Stegemann, M., Benstoem, C., & Fichtner, F. (2021). Remdesivir for the treatment of COVID‐19. The Cochrane Database of Systematic Reviews, 2021(8). https://doi.org/10.1002/14651858.CD014962
Buxeda, A., Arias-Cabrales, C., Pérez-Sáez, M. J., Cacho, J., Cabello Pelegrin, S., Melilli, E., Aladrén, M. J., Galeano, C., Lorenzo, I., Mazuecos, A., Saura, I. M., Franco, A., Ruiz-Fuentes, M. del C., Sánchez-Cámara, L. A., Siverio, O., Martin, M. L., González-García, E., López, V., Martin-Moreno, P. L., Crespo, M. (2021). Use and safety of remdesivir in kidney transplant recipients with COVID-19. Kidney International Reports, 6(9), 2305–2315. https://doi.org/10.1016/j.ekir.2021.06.023
Caricchio, R., Gallucci, M., Dass, C., Zhang, X., Gallucci, S., Fleece, D., Bromberg, M., & Criner, G. J. (2021). Preliminary predictive criteria for COVID-19 cytokine storm. Annals of the Rheumatic Diseases, 80(1), 88–95. https://doi.org/10.1136/ANNRHEUMDIS-2020-218323
Carothers, C., Birrer, K., & Vo, M. (2020). Acetylcysteine for the treatment of suspected remdesivir‐associated acute liver failure in COVID‐19: A case series. Pharmacotherapy, 40(11), 1166. https://doi.org/10.1002/PHAR.2464
Charan, J., Kaur, R. J., Bhardwaj, P., Haque, M., Sharma, P., Misra, S., & Godman, B. (2021). Rapid review of suspected adverse drug events due to remdesivir in the WHO database: Findings and implications. Expert Review of Clinical Pharmacology, 14(1), 95–103. https://doi.org/10.1080/17512433.2021.1856655
Dos Santos, W. G. (2020). Natural history of COVID-19 and current knowledge of treatment therapeutic options. Biomedicine & Pharmacotherapy, 129, 110493. https://doi.org/10.1016/J.BIOPHA.2020.110493
Jorgensen, S. C. J., Kebriaei, R., & Dresser, L. D. (2020). Remdesivir: Review of pharmacology, pre‐clinical data, and emerging clinical experience for COVID‐19. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 40(7), 659–671. https://doi.org/10.1002/phar.2429
Kiapidou, S., Liava, C., Kalogirou, M., Akriviadis, E., & Sinakos, E. (2020). Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Annals of Hepatology, 19(2), 134–144. https://doi.org/10.1016/j.aohep.2019.07.013
Gurala, D., Moussawi, H. Al, Philipose, J., & Abergel, J. R. (2020). Acute liver failure in a COVID-19 patient without any preexisting liver disease. Cureus, 12(8). https://doi.org/10.7759/CUREUS.10045
Lei, P., Zhang, L., Han, P., Zheng, C., Tong, Q., Shang, H., Yang, F., Hu, Y., Li, X., & Song, Y. (2020). Liver injury in patients with COVID-19: Clinical profiles, CT findings, the correlation of the severity with liver injury. Hepatology International, 14(5), 733–742. https://doi.org/10.1007/s12072-020-10087-1
Li, J., & Fan, J.-G. (2020). Characteristics and mechanism of liver injury in 2019 Coronavirus disease. Journal of Clinical and Translational Hepatology, 8(1), 1–5. https://doi.org/10.14218/JCTH.2020.00019
Mousapour, P., Farahani, R. H., Mosaed, R., Asgari, A., & Hazrati, E. (2022). Efficacy and safety of acetylcysteine for the prevention of liver injury in COVID-19 intensive care unit patients under treatment with remdesivir. Gastroenterology and Hepatology from Bed to Bench, 15(3), 241–248. https://doi.org/10.22037/GHFBB.V15I3.2565
Okwor, C., Meka, I., Nto-Ezimah, U., Nto, N., Nduka, N., Akinwande, K., & Edem, V. (2023). Association of SARS-CoV-2 viral load with biochemical profile of COVID-19 patients: A Nigerian experience. Nigerian Journal of Clinical Practice, 26(1), 109. https://doi.org/10.4103/njcp.njcp_1828_21
Sisay, M. (2020). Available evidence and ongoing clinical trials of remdesivir: Could it be a promising therapeutic option for COVID-19? Frontiers in Pharmacology, 11, 791. https://doi.org/10.3389/FPHAR.2020.00791/BIBTEX
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Y., Ding, D., Wu, F., Tang, X., Ye, Z., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, F.G., Horby, P.W., Cao, B., & Wang, C. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236), 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9
Yulistiani, Izka A, H., Rindang A, M., & A W, P. (2022). Tocilizumab therapy in COVID-19 patients. Pharmacy Education, 22(2), 259–262. https://doi.org/10.46542/pe.2022.222.259262
